Body Vision Medical Funding Backs LungVision AI Expansion

Body Vision Medical closed an undisclosed funding round on August 6, 2026, led by Business Asia Consultants, Inc. (BAC) and Sprim Global Investments. The Weston, Massachusetts-based medical technology company plans to use the capital to accelerate global expansion of LungVision®, its AI-powered intraoperative imaging platform for lung disease diagnosis and treatment.

The financing matters precisely because the headline number is missing. Body Vision Medical is not presenting investors with a theoretical market waiting for technology to arrive. LungVision has received FDA clearance and CE marking, has been deployed across 3 continents, and Body Vision Medical reports access to 46 countries through more than 20 distributors. Founder Dorian Averbuch and CEO Matt Baker are operating where healthcare AI, medical imaging, interventional pulmonology, and hospital infrastructure collide. The larger story is not simply another AI company raising money. Investors are backing technology designed to make clinical equipment hospitals already own more capable.

What Happened

Body Vision Medical closed the new financing with BAC and Singapore-based Sprim Global Investments leading the round. The company did not disclose the investment amount or valuation. The financing follows an $8.5M raise in 2018 and a $20M Series C in 2019. A reliable cumulative funding figure cannot be established from the supplied research because third-party databases report conflicting totals. In startup land, databases occasionally disagree like relatives splitting a restaurant bill, so leaving an uncertain number uncertain beats manufacturing precision.

The new capital is intended to support international expansion of LungVision. BAC already has history with Body Vision Medical through an international expansion partnership established in 2022 covering markets across Europe, Asia, and Latin America. That makes BAC more than a fresh investor name attached to an announcement. The relationship connects new capital with an existing market-development strategy.

Why Body Vision Medical and LungVision Matter

Dorian Averbuch founded Body Vision Medical in 2014 around a difficult bronchoscopy problem: the location of a pulmonary lesion on a preoperative CT scan can differ from where that lesion actually sits during the procedure. The discrepancy, known as CT-to-Body Divergence, can complicate navigation and biopsy targeting. When a clinician is navigating toward a suspected lung lesion, a few millimeters are not an interesting engineering footnote. Geography becomes medicine.

LungVision® addresses that problem using AI Tomo® technology and Tool-in-Lesion confirmation. The platform transforms standard 2D C-arm fluoroscopy into a 3D imaging and navigation environment for pulmonology and thoracic surgery, providing intraoperative visual information designed to help clinicians locate lesions and confirm instrument placement. Body Vision Medical says LungVision can move diagnostic yield from a 55%–75% baseline toward 90%+. The commercial thesis is unusually easy to understand: improve procedural visibility while working alongside infrastructure hospitals already own. The smartest infrastructure products sometimes make expensive things customers already have behave like more expensive things they do not.

Why This Funding Matters Now

Healthcare AI attracts plenty of attention when software summarizes clinical notes, automates administration, or assists a physician sitting at a screen. Body Vision Medical represents another layer of the market: AI moving into the physical procedure itself. That changes the stakes because intraoperative AI has to coexist with hardware, physician workflows, regulatory requirements, hospital economics, training, and the inconvenient reality that patients are not sandbox environments.

Body Vision Medical has already assembled several pieces of that commercial puzzle. LungVision has received FDA clearance and CE marking, while the company reports deployment across 3 continents and access to 46 countries through more than 20 distributors. The expansion strategy therefore starts with regulatory and distribution infrastructure rather than a map covered in hopeful arrows. For investors and healthcare operators, that may be the more interesting signal from this financing. Capital is following technology that has already crossed several of medtech's least glamorous but most important barriers.

Leadership and the Expansion Equation

CEO Matt Baker, who moved from COO into the CEO role in July 2024, leads Body Vision Medical alongside Dorian Averbuch, Founder, President, and Board Member. The validated leadership information supplied for this analysis also identifies Momi Karako as CFO; Yael Vin, MD, MPH, as CMO; Mike Hostetler as VP of Sales and Marketing; Benny Krauz as VP of Quality Assurance and Regulatory Affairs; Michal Beker as VP of Operations; and Ronni Epstein as Head of Human Resources. No current CTO was identified in the verified research, so none is being manufactured to make the organizational chart prettier.

Leadership matters because international medtech expansion is not merely a sales exercise wearing a lab coat. Regulatory affairs, clinical adoption, distribution, operations, hospital economics, and physician confidence have to move together. BAC and Sprim Global Investments are financing Body Vision Medical as that equation moves into additional international markets.

Market Context: AI Is Moving Into the Procedure Room

The Body Vision Medical funding reflects a broader healthcare AI shift from software that observes medicine toward systems that participate directly in clinical workflows. That distinction separates procedure-oriented medical AI from many generative AI applications dominating enterprise headlines. Defensibility in this category can emerge from the combination of algorithms, hardware compatibility, regulatory clearance, specialized clinical workflows, intellectual property, and distribution rather than from a model existing by itself.

LungVision's compatibility thesis is particularly relevant. Turning standard 2D C-arm fluoroscopy into a more advanced 3D imaging environment potentially gives hospitals another path to greater capability without beginning every purchasing conversation with wholesale equipment replacement. That is less cinematic than a humanoid robot walking onto a conference stage. Hospitals, fortunately, are not venture conferences. Healthcare systems care about clinical value, workflow disruption, capital budgets, training requirements, regulatory status, and whether technology survives contact with actual medicine.

What This Signals for Medtech Investors

The financing offers a useful business lesson beyond Body Vision Medical. AI alone is becoming an increasingly weak differentiator. Applied AI tied to specialized workflows, regulatory permissions, existing infrastructure, clinical use cases, and distribution creates a considerably harder commercial structure to reproduce.

Body Vision Medical has also spent years assembling those pieces. Dorian Averbuch founded the company in 2014. Body Vision Medical raised $8.5M in 2018, secured a $20M Series C in 2019, established its BAC international expansion relationship in 2022, and is now financing another stage of international growth in 2026. That timeline is an antidote to the idea that consequential technology markets move according to software launch calendars. Medtech compounds differently. Clinical evidence takes time, regulatory work takes time, distribution takes time, and physician trust really takes time. Occasionally, all that boring work becomes the interesting part.

The Bigger Industry Shift

Body Vision Medical sits inside a larger convergence of healthcare AI, medical imaging, minimally invasive intervention, and existing hospital infrastructure. The opportunity is not merely to produce a better image. It is to reduce the distance between identifying a suspected pulmonary lesion, navigating toward it, confirming location, obtaining diagnostic material, and supporting localized treatment.

That is why this financing deserves attention even without a disclosed dollar figure. BAC and Sprim Global Investments are financing international expansion around technology connecting software intelligence with physical clinical execution. Dorian Averbuch built Body Vision Medical around the problem of knowing where the target really is. Matt Baker now leads the company as that same question becomes commercial: how effectively can LungVision move across markets and clinical workflows? The check is undisclosed. The strategic direction is not.